2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1003

Use of Nsaids Correlates with the Risk of Venous Thromboembolism in Knee OA Patients: A UK Population-Based Case-Control Study
Abstract Number: 2415

Use of Plasma Exchange for Children Hospitalized with ANCA-Associated Vasculitis in the United States
Abstract Number: 428

Use of Rituximab Compared to Anti-TNF Agents As Second and Third Line Therapy in Patients with Rheumatoid Arthritis: 6-Year Follow-up Report from the Rhumadata® Clinical Database and Registry
Abstract Number: 263

Use of Serum Ferritin and Heme Oxygenase 1 for the Diagnosis of Adult-Onset Still’s Disease: A Preliminary Report of Multicenter Study
Abstract Number: 1012

Use of Social Media By Rheumatology Fellows in North America
Abstract Number: 47

Use of Social Media Data for Comparative Effectiveness and Safety Research: An Example from Rheumatoid Arthritis
Abstract Number: 577

Use of Subcutaneous MTX Does Not Prolong the Use of Traditional DMARD in Multi-DMARD Regimens and Has Insignificant Differences in Liver Enzymes Abnormalities When Compared with Oral MTX in Patients with Rheumatoid Arthritis: A Veteran Affairs Administrative Database Study
Abstract Number: 450

Use of Tofacitinib in a Real World Setting: Clinical Features in a Cohort of Patients Using the Database Jointman Compared to a Published Clinical Trial
Abstract Number: 631

Usefulness of the Minimally-Invasive Minor Salivary Gland Biopsy in Patients Presenting with Sicca Syndrome: Prospective Evaluation of 200 Patients
Abstract Number: 156

Usefulness of the Stricter Remission Criteria for Assessing the Absence of Subclinical Activity in Rheumatoid Arthritis
Abstract Number: 2950

Using Electronic Health Record Algorithms to Accurately Identify Patients with Systemic Lupus Erythematosus
Abstract Number: 3229

Using Exome Sequencing to Identify Novel Genetic Associations with Granulomatosis with Polyangiitis Susceptibility
Abstract Number: 2440

Using Patient-Relevant Variables to Describe the Disease Course in Children with Juvenile Idiopathic Arthritis
Abstract Number: 2161

Ustekinumab for the Treatment of Refractory Giant Cell Arteritis
Abstract Number: 636

Utility of IgA Anti-Alpha-Fodrin Antibodies in Combination with Rheumatoid Factor and/or Antinuclear Antibodies As Substitute Immunological Criterion for Sjögren’s Syndrome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].